// STATE LEGISLATION TRACKER

Louisiana HC R120 — INSURANCE: Creates the PACE Task Force to prioritize access, care, and education on GLP-1 medications

⚖️ NEUTRAL for peptide users 👤 LOW user impact 📜 Status: Unknown

State: Louisiana
Bill: HC R120
Session: 2026
Filed: 2026-05-28
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

Louisiana HCR120 appears to create a PACE Task Force focused on access, care, and education around GLP-1 medications. Based only on the title, subjects, and lack of recorded actions, it does not directly change compounded peptide access, off-label prescribing, telehealth rules, clinician scope, FDA compounding rules, controlled substances, or prescription monitoring.

Key Points

No direct change to peptide prescribing or compounding is shown
GLP-1 access and education may become a state policy focus
Insurance coverage could be discussed by the task force
Compounded GLP-1 use is not specifically addressed in the available info

What to Watch For

✓

Opportunity Task force recommendations could support broader GLP-1 coverage or patient education.

Concern Future recommendations could favor FDA-approved GLP-1 drugs over compounded versions.

Note No recorded actions means the bill status and practical effect are unclear from the source.

Where the Bill Stands

The source lists no recorded actions, so its position in the legislative process cannot be confirmed from the available information.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws